Final draft guidance published by Nice shows NHS England requested that Mounjaro is rolled out over a period of 12 years. The watchdog recommends prioritising patients receiving care from specialist ...

After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals.

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.

Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds. But obesity experts say ...